IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome immune profiling platform will be used to study cellular drivers of durable and protective immune response to the virus.
Union Therapeutics has completed an agreement with TFF Pharmaceuticals to obtain a worldwide exclusive license for the use of its thin film freezing technology in combination with niclosamide to focus on treatments for COVID-19.
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming months. Such collaboration could change the way that innovation and competition are viewed in the biopharmaceutical industry, according to a policy forum published in Science on August 13. Discuss
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Akeso for Ak104, a bispecific antibody, as a monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer.
Prometheus Biosciences has entered into an agreement with Dr. Falk Pharma for the development and commercialization of Pr600, a novel precision antibody, for the treatment of inflammatory bowel disease (IBD).
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate from its Seattle facility.
Bio-Techne has launched a SARS-CoV-1/2 spike receptor-binding domain LlamaBody recombinant antibody that blocks the virus from binding to the host receptor, angiotensin-converting enzyme 2.
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and manufacturing capabilities, in part due to COVID-19.
SAB Biotherapeutics has started a phase I trial evaluating SAB-185 for the treatment of COVID-19.
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation -- using computers to simulate drug response in humans -- can help accelerate the process, which Certara hopes to achieve with a newly launched platform targeted at COVID-19 vaccine development. Discuss
Conferences
ACS Fall 2020 Virtual Meeting & Expo
August 17-20
August 17-20
ESMO Virtual Congress 2020
September 14-29
September 14-29
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
|
General Discussion
|
||
| Topic | Replies / Views | Last Update |
|---|---|---|
|
Childhood vaccines may help protect against COVID-19 mortality
|
0 / 6 | More than 3 days ago |
|
https://academic.oup.com/ve/pages/coronavirus-evolution
|
0 / 49 | More than 3 days ago |
|
PopSci Hails Impossible Burger 2.0 as Most Important Engineering Innovation in 2019
|
0 / 14 | More than 3 days ago |
|
Engineered Bacteria Produces BeeFree Honey
|
0 / 13 | More than 3 days ago |
|
Consumers' Preference to Buy Unlabeled Produce Increases after Exposure to GMO-labeled Pro
|
0 / 15 | More than 3 days ago |
| To see more posts from our community or to share a post of your own, go to our community's forum page. | ||
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
